This is a pre-commercialization awareness effort ahead of potential FDA approval of QTORIN™ rapamycin. Traders should monitor upcoming clinical trial data (e.g., TOIVA study) and regulatory milestones as potential catalysts. Insider buying in the past 30 days may signal confidence in future developments.
Price Chart
Executive Summary
Palvella Therapeutics launched the 'BEYOND mLM' disease awareness campaign and website (BEYONDmLM.com) to educate patients, caregivers, and healthcare providers about microcystic lymphatic malformations (microcystic LMs), a rare and debilitating condition with no FDA-approved therapies. The campaign was developed in collaboration with leading nonprofit organizations and clinical experts in the vascular anomalies community.
Key Facts
- Palvella launched BEYONDmLM.com, an educational campaign and website focused on microcystic lymphatic malformations (microcystic LMs).
- The campaign was developed in partnership with five key nonprofit organizations: CaNVAS, LGDA, LE&RN, PeDRA, and VAccess.org.
- Microcystic LMs affect over 30,000 diagnosed patients in the U.S. and are characterized by malformed lymphatic vessels causing chronic leakage, bleeding, and recurrent infections.
- There are currently no FDA-approved treatments for microcystic LMs.
- Palvella’s lead investigational product, QTORIN™ rapamycin gel, is in development for this condition.
Financial Impact
No direct financial impact disclosed; campaign is educational and awareness-focused.
Risk Factors
- No guarantee that increased awareness will translate into future product adoption.
- QTORIN™ rapamycin remains investigational and may not achieve regulatory approval or commercial success.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3252673 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 4w ago | 144 | $155.47 $132.47 | ▼ −14.79% | ▼ −13.61% | $132.47 (−14.79%) |
Aug 9, 2026 7w ago | Institutional Cluster | $152.22 $157.00 | ▲ +3.14% | ▲ +4.05% | $132.47 (−12.97%) |
Aug 4, 2026 8w ago | 8-K | $151.99 $150.55 | ▼ −0.95% | ▲ +0.29% | $132.47 (−12.84%) |
Jul 30, 2026 9w ago | Press Release | $150.19 $150.33 | ▲ +0.09% | ▼ −3.87% | $132.47 (−11.80%) |
Jul 28, 2026 9w ago | Press Release | $142.84 $148.24 | ▲ +3.78% | ▲ +0.40% | $132.47 (−7.26%) |
Jun 30, 2026 13w ago | 8-K | $152.82 $141.77 | ▼ −7.23% | ▼ −6.20% | $132.47 (−13.32%) |
Jun 22, 2026 14w ago | Press Release | $118.84 $157.24 | ▲ +32.31% | ▲ +32.46% | $132.47 (+11.47%) |
Jun 16, 2026 15w ago | 8-K | $110.12 $149.68 | ▲ +35.92% | ▲ +35.72% | $132.47 (+20.30%) |
Jun 11, 2026 16w ago | Institutional Cluster | $106.38 $151.04 | ▲ +41.98% | ▲ +40.09% | $132.47 (+24.53%) |
May 15, 2026 20w ago | 8-K | $114.24 $116.51 | ▲ +1.99% | ▼ −0.13% | $132.47 (+15.96%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access